Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National and Kapodistrian University of Athens
With
Andreas Syggros Hospital of Venereal and Dermatological Diseases
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Moderate-to-severe psoriasis (Psoriasis Area Severity Index (PASI) score \> 10 or Body Surface Area (BSA) \>10 or Dermatology Life Quality Index (DLQI) \>10)
Indication for treatment with an IL17 or an IL23 inhibitor based on disease characteristics and comorbidities
You may not be if
Prior treatment with an IL17 or an IL23 inhibitor
Prior therapy with an TNFa-inhibitor for up to 3 months before entering the study
